Drugs / GEN1160
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05721222 | Mar 2023 → Nov 2025 | nasopharyngeal carcinoma, non-Hodgkin lymphoma, renal cell carcinoma | Genmab | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GEN1160 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05721222 ↗ |
| Known as | PRO1160 | “GEN1160 (PRO1160)” NCT05721222 ↗ |
| Route | Intravenous | “IV infusion of GEN1160” NCT05721222 ↗ |
| Target | CD70 | “a CD70 targeted antibody-drug conjugate” NCT05721222 ↗ |